GALWAY, IRELAND--January 22, 2024--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Buoyed by the runaway success of its diabetes and weight loss drugs Ozempic and Wegovy, Denmark's Novo Nordisk A/S (NYSE:NVO) (Bagsværd, Denmark) has plans to build a major manufacturing operation at its Grange Castle campus in Dublin, Ireland. Within this article: Details new plant investment in Dublin to boost production of Ozempic and Wegovy, scale, timeline, related European investments
(All Fields Required)
Site-wide Scheduled Maintenance for September 27, 2025 from 12 P.M. to 6 P.M. CDT. Expect intermittent web site availability during this time period.
×Contact Us
For More Info!